Thread by @michaelzlin on Thread Reader App
More details on Novavax approval. I am not convinced anyone will be able to “self-report” medical condition allowing access if under 65, as author hopes.
New RCT study shows the "conventional" Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options.
“New RCT study shows the ‘conventional’ Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options. Side effects are a leading cause of COVID vaccine hesitancy. This can help.”
Another paper from the PICOBOO randomized trial, evaluating second boosters after mRNA priming.
A trio of Novavax preprints, showing 1) remarkable durability 6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.
“A trio of Novavax preprints, showing 1) remarkable durability >6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.”
Novavax reduces viral load by over 600x. If you have a choice, Novavax is the superior vaccine for everything that matters: effectiveness and safety.
“Novavax reduces viral load by over 600x. If you have a choice, Novavax is the superior vaccine for everything that matters: effectiveness and safety.”